Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

TherapeuticsMD Posts $501,000 Third-Quarter Net Income as License Revenue Rises 61%

None

TherapeuticsMD (TXMD) reported third-quarter 2026 net income from continuing operations of $501,000, or $0.04 per basic and diluted common share. License revenue totaled $1.3 million, up 60.6% from $784,000 in the prior-year quarter.

The pharmaceutical royalty company said it continues to evaluate strategic alternatives, including a potential acquisition, merger, business combination, asset sale or other transaction.

  • Total operating expenses from continuing operations were $1.7 million, up $92,000, or 5.6%, from the third quarter of 2025.
  • Cash and cash equivalents totaled $10.4 million as of September 30, 2026.
  • The license-revenue increase included a $365,000 IMVEXXY sales-based milestone payment recognized during the quarter.
  • After quarter-end, Knight notified the company that another IMVEXXY net-sales milestone for the year ending December 31, 2026, had been achieved; TherapeuticsMD expects to recognize related revenue in the fourth quarter.

$TXMD Hedge Fund Activity

We have seen 16 institutional investors add shares of $TXMD stock to their portfolio, and 17 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles